- Home
- / Sutro Biopharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Sutro Biopharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.5
2024-10-29
Market Capitalization
$294.3 M
2024-10-29
Revenue
$102.5 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 61.9M | 67.8M | 153.7M | 62.0M | 102.5M |
| General and administrative expense | 56.0M | 59.5M | 62.6M | 48.5M | 41.0M |
| Operating expense total | 160.4M | 196.7M | 243.0M | 300.5M | 207.4M |
| EBIT | (98.5M) | (128.9M) | (89.3M) | (238.5M) | (158.4M) |
| EBIT margin, % | -159.2% | -190.3% | -58.1% | -384.3% | -154.5% |
| Investment income | 577.0K | 3.5M | 14.5M | 18.6M | 9.3M |
| Interest expense | 310.0K | ||||
| Pre tax profit | (116.7M) | (88.6M) | (225.1M) | (191.2M) | |
| Income tax expense | 2.5M | 18.2M | 2.4M | (100.0K) | |
| Net Income | (105.5M) | (119.2M) | (106.8M) | (227.5M) | (191.1M) |
| EPS | (2.3) | (2.3) | (1.8) | (3.0) | (22.5) |